Evidence map›Paper›PMID 24575098›Full record

ReviewFrontiers in immunology2014

The Interplay between Daptomycin and the Immune System.

Theodoros Kelesidis

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in immunology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 39 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Antibiotics and Bacterial Resistance-A Short Story of an Endless Arms Race.International journal of molecular sciences · 2023
    Review
  6. Review
  7. Article
  8. Clinical Pharmacokinetics of Daptomycin.Clinical pharmacokinetics · 2021
    Review
  9. The ecological roles of microbial lipopeptides: Where are we going?Computational and structural biotechnology journal · 2021
    Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Spirochetal Lipoproteins and Immune Evasion.Frontiers in immunology · 2017
    Review
  15. Article
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Theodoros KelesidisDepartment of Medicine, Division of Infectious Diseases, David Geffen School of Medicine, University of California , Los Angeles, CA , USA.
University of California, Los Angeles · US

Funding

UCLA Clinical and Translational Science InstituteUL1TR000124 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DUBINETT, STEVEN M. · 2012 to 2015
$57.0M
Oxidized HDL in the intersection of HIV, immune activation and atherosclerosisK08AI108272 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI KELESIDIS, THEODOROS · 2013 to 2017
$915k
NCATS NIH HHS UL1 TR000124NIAID NIH HHS K08 AI108272
6 · The paper itself

Abstract

Antibiotics may have bacteriostatic or bactericidal effects but may also cause immunomodulation. Lipopeptides are known immunomodulators that interact with pattern recognition receptors such as Toll-like receptors in antigen presenting cells. Daptomycin is a novel lipopeptide antibiotic with a lipid moiety and unique structure that in the presence of divalent ions may directly interact with lipid membrane phospholipids, the major component of lipid membranes in immune cells. Daptomycin may also penetrate immune cells including neutrophils and macrophages. However, the possible immunomodulatory effects of daptomycin remain unknown. Understanding these effects is important to determine whether this agent can provide protection against infectious challenge through multiple mechanisms. Preliminary studies suggest that daptomycin may have minimal effects on cytokine production and may have synergistic immunomodulatory effects in combination with other immunomodulators. This review focuses on the hypothesis that daptomycin may also have immunomodulatory effects but further studies are needed to investigate this hypothesis.

Indexed as

antibioticsdaptomycinimmunityimmunomodulationlipopeptide

Identifiers

PMID24575098
PMCPMC3921582
OpenAlexW2169722093

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.